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Abstract
Background: The envelope glycoproteins (Env), gp120 and gp41, are the most variable proteins of human
immunodeficiency virus type 1 (HIV-1), and are the major targets of humoral immune responses against HIV-1. A
circulating recombinant form of HIV-1, CRF01_AE, is prevalent throughout Southeast Asia; however, only limited
information regarding the immunological characteristics of CRF01_AE Env is currently available. In this study, we attempted
to examine the evolutionary pattern of CRF01_AE Env under the selection pressure of host immune responses.
Methodology/Principal Findings: Peripheral blood samples were collected periodically over 3 years from 15 HIV-1-infected
individuals residing in northern Thailand, and amplified env genes from the samples were subjected to computational
analysis. The V5 region of gp120 showed highest variability in several samples over 3 years, whereas the V1/V2 and/or V4
regions of gp120 also showed high variability in many samples. In addition, the N-terminal part of the C3 region of gp120
showed highest amino acid diversity among the conserved regions of gp120. Chronological changes in the numbers of
amino acid residues in gp120 variable regions and potential N-linked glycosylation (PNLG) sites are involved in increasing
the variability of Env gp120. Furthermore, the C3 region contained several amino acid residues potentially under positive
selection, and APOBEC3 family protein-mediated G to A mutations were frequently detected in such residues.
Conclusions/Significance: Several factors, including amino acid substitutions particularly in gp120 C3 and V5 regions as
well as changes in the number of PNLG sites and in the length of gp120 variable regions, were revealed to be involved in
the molecular evolution of CRF01_AE Env. In addition, a similar tendency was observed between CRF01_AE and subtype C
Env with regard to the amino acid variation of gp120 V3 and C3 regions. These results may provide important information
for understanding the immunological characteristics of CRF01_AE Env.
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Introduction
Human immunodeficiency virus type-1 (HIV-1) is characterized
by extensive genetic heterogeneity [1], and is divided into four
groups, M (major), O (outlying), N (new or non-M, non-O) and P
(pending). The viruses in group M are further classified into many
subtypes and circulating recombinant forms (CRFs). Among them,
subtypes A, B, C, D and G, as well as CRF01_AE and
CRF02_AG, are the major subtypes and CRFs, which are
responsible for the worldwide HIV-1 pandemic [2]. While subtype
B of HIV-1 is the predominant subtype in the Americas, Europe
and Australia, there is a growing epidemic of non-B subtypes and
CRFs in Africa and Asia. CRF01_AE is prevalent throughout
Southeast Asia [2], and is responsible for more than 80% of
infection cases in Thailand [3].
The heterogeneity of the HIV-1 genome is mainly attributed to
the error-prone nature of viral reverse transcriptase [4]. In the
reverse transcription process, a G to A hypermutation is
introduced into proviral DNA by the APOBEC3 family of
cytosine deaminases [5,6,7,8]. Although several lines of evidence
have demonstrated that APOBEC3 family protein-mediated
hypermutation plays an important role in the host defense
mechanism against HIV-1 in a clinical setting [9,10,11,12,13], a
sub-lethal level of APOBEC3 activity probably affect viral
evolution, which facilitates viral escape from immune responses
and antiretroviral therapy (ART) [14,15].
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play a central role in viral transmission to target cells, and
mediate attachment and incorporation of the virus into the cells
through specific interaction with the CD4 receptor and
chemokine receptors. In addition, Env is a major target of
humoral immune responses against HIV-1 [16,17]. Env gp120
and gp41 are the most variable HIV-1 proteins with typical
intersubtype and intrasubtype differences soaring to 35% and
20%, respectively [1]; therefore, the humoral immune responses
against Env potentially somewhat vary among different subtypes
and CRFs. For example, the replication of many clinical isolates
of subtype B, C and D is neutralized by a human monoclonal
antibody against the CD4 binding site (CD4BS) of Env gp120,
IgG1 b12, which was established from an HIV-1 subtype B-
infected individual [18], while most CRF01_AE viruses are
resistant to IgG1 b12-mediated neutralization [19,20,21]. In
addition, recently established, broadly neutralizing human
monoclonal antibodies derived from HIV-1 subtype A-infected
individuals recognize conserved regions of the V2 and V3 regions
[22], while several broadly neutralizing, human or murine
monoclonal antibodies elicited by the HIV-1 subtype B anti-
gen recognize CD4BS or V3 region of Env gp120
[18,23,24,25,26,27]. These results imply that the Env of different
subtypes and CRFs show different antigenicity.
The introduction of mutations into HIV-1 Env, including those
involved in the N-linked glycosylation of particular amino acid
residues, leads to a reduction of the susceptibility to neutralizing
antibodies [28,29,30]; therefore, the mutation-driven evolution of
HIV-1 Env plays an important role in conferring viral escape from
humoral immune responses. In order to study the evolutionary
pattern of CRF01_AE Env under host immune pressure, we
examined the changes of HIV-1 Env amino acid sequences
derived from chronically CRF01_AE-infected Thai patients over 3
years.
Methods
Ethics statement
This study was conducted with the approval from the ethics
committee of the Department of Medical Sciences, Ministry of
Public Health of Thailand and with written informed consent from
the patients.
Study participants and sample collection
Peripheral blood samples were collected every 3 months from
April 2008 to January 2011, namely 12 times in total, from 9 drug-
naı ¨ve, HIV-1-infected patients as well as from 6 HIV-1-infected
patients on ART. All patients were infected with HIV-1
CRF01_AE viruses [31], and were negative for hepatitis B and
C viruses at the time of enrollment. Among 9 drug-naive patients,
4 patients started ART during the project.
Measurement of CD4 count and viral load
As clinical markers, the CD4 count and viral load of the patients
were monitored during the study period. The CD4 count was
measured every 3 months by flow cytometric analysis at Chiangrai
Prachanukoh Hospital, according to the manufacturer’s protocol
(Beckman Coulter, Fullerton, California, USA). In addition, the
viral load was measured every 6 months as follows. Viral RNA was
extracted from a plasma sample using High Pure System Viral
Nucleic Acid (Roche, Basel, Switzerland). The viral load was then
measured using the Cobas AmpliPrep/Cobas TaqMan HIV-1
version 5.1 Assay (Roche).
Amplification of viral genomic fragment encoding a full
length Env precursor gp160
Plasma was isolated from peripheral blood samples by
centrifugation for 10 min at 2000 rpm. In addition, peripheral
blood mononuclear cells (PBMC) were isolated by density gradient
centrifugation using Ficoll-Paque (GE Healthcare, Buckingham-
shire, UK). Prior to RNA extraction, viral particles were
concentrated from 1-2 ml of plasma by ultracentrifugation for
1 hour at 65,000 rpm using TLA-100.3 rotor with Optima TLX
ultracentrifuge (Beckman Coulter). RNA and DNA were then
extracted from the concentrated viral particles and PBMC using
the QIAamp viral RNA mini-kit and the QIAamp DNA blood
mini-kit (Qiagen, Hilden, Germany), respectively. Viral RNA was
reverse transcribed to cDNA using the SuperScript III First-Stand
Synthesis kit (Invitrogen, Carlsbad, California, USA) with the
reverse primer, K-env-R1, 59-CCAATCAGGGAAGAAGC-
CTTG-39 [corresponding to nucleotide (nt) 8736 to 8716 of
CRF01_AE reference strain, CM240 (GenBank accession no.
U54771)]. The HIV-1 genomic fragment, encoding full-length
Env precursor gp160, Rev and Vpu as well as partial fragments of
Tat and Nef, was then amplified by nested PCR using BIO-X-
ACT DNA polymerase (Bioline, Luckenwalde, Germany) and one
of two primer sets, as follows. As the first set of primers, N-env-F1;
59-TTAGAGGAGCTTAAAAATGAAGC-39 (nt 5193 to 5215)
and N-env-R1; 59-TTAAAAAGAAGCTAAGATCAAAAGC-39
(nt 8638 to 8614) were used for the first PCR, and N-env-F2; 59-
GAATTGGGTGTCAACATAGCAGAATAGGC-39 (nt 5344 to
5372) and N-env-R2; 59- TATCTAGATCTTGAGATACT-
GCTCC-39 (nt 8485 to 8461) were used for nested PCR. As the
second set of primers, K-env-F1; 59- CTAGAGCCCTGGAAT-
CATCCG-39 (nt 5419 to 5439) and K-env-R1; 59- CCAAT-
CAGGGAAGAAGCCTTG-39 (nt 8736 to 8716) were used for
the first PCR, and K-env-F2; 59-CGAGGAACTCCTCAGAG-
CAG-39 (nt 5563 to 5582) and K-env-R2; 59-TCTTG-
TGCTCTCAGCCAGAC-39 (nt 8549 to 8530) were used for
nested PCR. If the PCR using the first set of primers failed to
amplify viral genomic fragment, the second set of primers was
used. The PCR conditions were as follows. For the 1st PCR using
the first set of primers, one cycle of 1 min at 94uC for
denaturation; 10 cycles of 20 sec at 94uC for denaturation, 30
sec at 48uC for annealing and 5 min at 68uC for extension; 20
cycles of 10 sec at 94uC for denaturation, 30 sec at 48uC for
annealing and 5 min at 68uC for extension with cycle elongation of
10 sec for each cycle; and a final extension cycle of 10 min at 68uC
were carried out. For the nested PCR using the first set of primers,
one cycle of 1 min at 94uC for denaturation; 30 cycles of 10 sec at
94uC for denaturation, 30 sec at 52uC for annealing and 4 min at
68uC for extension with cycle elongation of 5 sec for each cycle;
and a final extension cycle of 5 min at 68uC were carried out. For
the 1st and nested PCR using the second set of primers, annealing
temperatures were changed to 60uC and 58uC, respectively. If a
viral gene fragment failed to be amplified from the cDNA
generated from viral RNA even after multiple attempts, it was
amplified instead from DNA extracted from PBMC. In order to
examine the genomic fragment of the major viral population in a
sample, PCR products amplified at the end-point dilution of
cDNA or DNA templates were subjected to sequencing analysis.
Sequencing and data analysis
Sequencing analysis of the amplified HIV-1 genomic fragment
was carried out using the BigDye Terminator v3.1 Cycle
Sequencing kit with an ABI PRISM 3130XL genetic analyzer
(Applied Biosystems, Foster City, California, USA), and data were
assembled using SeqScape v2.5 software (Applied Biosystems).
Evolution of CRF01_AE Viruses
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patient were then aligned with the viral sequence derived from the
earliest sample collected in April 2008, using the ClustalW
algorithm [32] with slight manual adjustment, followed by the
numbering of amino acid residues according to their position in
the HXB2 Env (Genbank accession no. K03455). Pairwise genetic
distances between two amino acid sequences derived from an
individual patient were calculated by using the p-distance model
with 1,000 bootstrap replicates, conducted with the MEGA5
software package [33]. The diversity of each amino acid residue
among 10 amino acid sequences derived from an individual was
evaluated by calculating the Shannon index [34] with a program
available at the website, http://www.gen-info.osaka-u.ac.jp/˜
uhmin/study/consensus/index.html. The nonsynonymous to
synonymous substitution rate (dN/dS ratio) was estimated by
calculating the numbers of synonymous substitutions per synon-
ymous site (dS) and nonsynonymous substitutions per nonsynon-
ymous site (dN) based on the Tamura-Nei method using the
HyPhy program in the MEGA5 software package [33,35]. Finally,
the potential N-linked glycosylation (PNLG) site was evaluated
using N-Glycosite (http://www.hiv.lanl.gov/).
Nucleotide sequence accession numbers
The nucleotide sequences of the viral gene fragment encoding
full-length Env precursor gp160 have been deposited in the
GenBank database under accession numbers JN388081-
JN388230.
Results
Sample collection from 15 Thai patients infected with
HIV-1 CRF01_AE viruses. The molecular evolution of
CRF01_AE Env, which was presumably driven by the selection
pressure of humoral immune responses, was studied in this report.
To this end, we periodically collected 10-12 viral sequences
encoding full-length Env precursor gp160 for 3 years from 15 Thai
patients chronically infected with HIV-1 CRF01_AE viruses, and
performed computational analysis on 10 selected viral sequences
derived from each patient (Table S1). We attempted to study viral
sequences derived from plasma viral RNA; however, if a viral gene
fragment failed to be amplified from viral RNA, that derived from
proviral DNA was instead studied. Proviral DNA is generally
considered to be more heterogeneous than viral RNA; however,
the concordance of viral sequences between viral RNA and the
major population of proviral DNA was observed previously
[36,37,38]. Indeed, homogeneous viral sequences were amplified
at the end-point dilution of proviral DNA samples (data not
shown). The CD4 count and viral load were measured as clinical
markers during the study (Tables S2 and S3). The CD4 counts of
most patients were relatively stable, but fluctuated over 3 years
(Table S2). In addition, the CD4 counts of 4 drug-naive patients
Figure 1. Variability of amino acid sequences in Env gp120 regions and gp41. Nine amino acid sequences derived from samples collected
between July 2008 and January 2011 from an individual were aligned with the amino acid sequence derived from the earliest sample collected in
April 2008 from a corresponding individual. Aligned sequences were then divided into variable and conserved regions of gp120 and gp41. Pairwise
genetic distances (p-distance) between the sequences derived from the earliest and one of the later samples was determined as described in
Methods. The data obtained for all Env regions were plotted together in chronological order of sampling, as indicated from 1 vs 2 to 1vs 10. Patient
IDs, Env regions and the status of treatment are denoted above, below and beside the panels, respectively.
doi:10.1371/journal.pone.0027098.g001
Figure 2. Amino acid residues with high diversity in the C3 and V5 regions of gp120. The Shannon index was calculated for each amino
acid residue in the C3 and V5 regions of gp120 among 10 amino acid sequences derived from an individual, as described in Methods. The data
obtained from 15 patient samples were then plotted together. Amino acid numbering is based on the HXB2 Env gp120.
doi:10.1371/journal.pone.0027098.g002
Evolution of CRF01_AE Viruses
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3, and subsequently
increased in response to ART (Table S2). The viral loads of the
patients on ART were close to or under the detection limit
throughout the study, whereas these of drug-naive patients
gradually increased during the study (Table S3). These results
suggested that the clinical conditions of most patients were
relatively stable over 3 years, but those of some patients gradually
deteriorated during the study.
Variability of CRF01_AE Env gp120 and gp41 over 3 years
After the establishment of HIV-1 infection, the amino acid
diversity of HIV-1 Env increases during the course of disease
progression [39]. In order to evaluate the molecular evolution of
the functional regions of CRF01_AE Env under the pressure of
humoral immune responses, we studied the variability of amino
acid sequences in the conserved and variable regions of Env
gp120 as well as in gp41. To this end, pairwise genetic distances
(p-distances) between the amino acid sequences of an Env
region in the earliest and one of the later samples derived from
an individual were determined, and were plotted together to
compare the variability of each Env region over 3 years. The
results showed that the pairwise genetic distances of the amino
acid sequences in gp120 variable regions, V1-V5, were higher
than in other regions, including the conserved regions, C1-C5,
of gp120 and gp41, as expected (Fig. 1). The V5 region showed
the highest variability in samples derived from 8 individuals,
CR2, CR3, CR14, CR15, CR11, CR17, CR25 and CR29,
w h e r e a st h eV 1 / V 2o rV 4r e g i o n ( s) showed higher variability
than the V5 region in samples derived from 7 individuals,
CR10, CR8, CR12, CR19, CR28, CR36 and CR38 (Fig. 1). V3
region showed relatively low variability among variable regions
(Fig. 1). In addition, C3 showed the highest variability among
the conserved regions of gp120 (Fig. 1). Pairwise genetic
distances of amino acid sequences in 5 conserved regions are
also shown in Figure S1. Finally, gp41 showed lower variability
than gp120 in all samples (Fig. 1). There were two patterns of
change in the amino acid variability of Env gp120 and gp41
over 3 years. One was a gradually increasing pattern (example;
CR3, V1/V2 regions), while the other was a fluctuating pattern
of variability during 3 years (example, CR2, C3 region)
(Figs. 1 and S1).
High amino acid diversity in the N-terminal part of C3
region and in entire V5 region
C3 and V5 regions showed the highest variability among the
conserved and variable regions of gp120, respectively (Figs. 1 and
S1). We next attempted to determine amino acid residues with
high diversity within these regions by calculating the Shannon
index of diversity. The Shannon index is a diversity index used to
measure diversity in categorical data. We calculated the index for
each amino acid residue in the C3 and V5 regions of gp120
among 10 viral sequences derived from an individual. The results
showed that the N-terminal, but not C-terminal part of the C3
region contained amino acid residues with Shannon index values
of 0.5-2.5 in many samples, indicating that high amino acid
diversity was observed in the N-terminal part of the C3 region
(Fig. 2). In addition, most amino acid residues, except a few
amino acid residues at N- and C-termini, of the V5 region
showed high diversity (Fig. 2). A large amino acid insertion was
found in the middle part of the V5 region of gp120 in a few
samples, and these amino acid residues also showed high diversity
(Fig. 2).
Variations in the length of gp120 variable regions and
the number of PNLG sites
The length of the variable regions of gp120 as well as the N-
linked glycosylation of particular amino acid residues affect the
protein structure and lead to changes in the neutralization
susceptibility of HIV-1 Env [17,30,40]; therefore, these factors
are important for the molecular evolution of HIV-1 Env. We
studied the changes in the numbers of amino acid residues and
PNLG sites in the functional regions of gp120 and gp41. Average
numbers of amino acid residues and PNLG sites in each Env
region are shown in Table 1. The amino acid numbers did not
significantly change over 3 years in the C1, C2, V3, C4 and C5
regions of gp120 as well as in gp41 (data not shown). In contrast,
the numbers of amino acid residues in the V1/V2, C3, V4 and V5
regions of gp120 varied among samples derived from different
individuals, and the numbers changed over 3 years (Fig. 3). A
moderate correlation was observed between the variability and the
chronological change of amino acid numbers in V1/V2, V4 and
V5 regions (Figs. 1 and 3). Namely, if the chronological changes,
either increasing or decreasing, in amino acid numbers were
frequent (Fig. 3), the variability of the Env regions were high in
some samples (examples; V1/V2 regions of CR2, V4 region of
CR11, V5 region of CR14) (Fig. 1). The number of PNLG sites
changed significantly in the V1/V2 and V4 regions of gp120 over
3 years, whereas only a few chronological changes were observed
in the number of PNLG sites in the C1, C2, V3, C3, C4 and V5
regions of gp120 as well as in gp41 (Fig. 4 and data not shown). A
moderate correlation was again observed between the variability
and the chronological change in the number of PNLG sites in the
V1/V2, C3 and V4 regions of gp120 (Figs. 1, S1 and 4).
Detection of the amino acid residues potentially under
positive selection
We next attempted to determine the amino acid residues in
gp120 and gp41 under positive selection. To this end, the dN/dS
ratio was calculated, and an amino acid residue with a ratio
greater than 1 was considered to be potentially under positive
selection. Since insertion and deletion mutations were frequently
Table 1. Average numbers of amino acid residues and
potential N-linked glycosylation (PNLG) sites in Env regions.
Env regions
Number of amino
acid residues* Number of PNLG sites*
gp120
C1 129.960.7 1.960.5
V1/V2 72.469.1 6.461.6
C2 99.961.1 6.460.8
V3 34.160.3 0.760.4
C3 53.161.0 2.660.6
V4 26.064.3 3.661.2
C4 40.0601 . 3 60.5
V5 10.662.8 1.760.7
C5 42.0600
gp41 352.862.6 4.260.7
*The number of amino acid residues in an Env region was counted manually.
PNLG sites were evaluated using N-Glycosite, and then counted manually. The
means and standard deviations of the data calculated using 150 Env sequences
derived from 15 individuals are shown.
doi:10.1371/journal.pone.0027098.t001
Evolution of CRF01_AE Viruses
PLoS ONE | www.plosone.org 5 November 2011 | Volume 6 | Issue 11 | e27098Figure 3. Changes in the number of amino acid residues in the gp120 regions. The numbers of amino acid residues in the gp120 regions
were counted manually for 10 amino acid sequences derived from an individual. The data obtained from 15 patient samples were then plotted
together in chronological order of sampling, as indicated from 1 to 10. Env regions are denoted above the panels, whereas patient IDs and the status
of treatment are denoted below the panels.
doi:10.1371/journal.pone.0027098.g003
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PLoS ONE | www.plosone.org 6 November 2011 | Volume 6 | Issue 11 | e27098Figure 4. Changes in the number of PNLG sites in the gp120 regions. PNLG sites in the gp120 regions were evaluated using N-Glycosite, and
the number of the sites was then counted manually for 10 amino acid sequences derived from an individual. The data obtained from15 patient
samples were then plotted together in chronological order of sampling, as indicated from 1 to 10. Env regions are denoted above the panels,
whereas patient IDs and the status of treatment are denoted below the panels.
doi:10.1371/journal.pone.0027098.g004
Evolution of CRF01_AE Viruses
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years in many samples (Fig. 3), we failed to estimate reliable dN
and dS values following the alignment of amino acid sequences for
these variable regions. In contrast, the dN/dS ratios of the amino
acid residues in the V3 and five conserved regions of gp120 as well
as in gp41 were successfully determined. We found that the dN/dS
ratios were greater than 1 at 6, 5, 3, 17, 7, 0 and 9 amino acid
residues in the C1, C2, V3, C3, C4 and C5 regions of gp120 and
gp41, respectively, in samples derived from at least one individual
(Table 2). The C3 region of gp120 contained several amino acid
residues with a dN/dS ratio greater than 1 (Table 2). The dN/dS
ratios of amino acid residues in C3 region are shown in Figure 5.
Our results showed that several amino acid residues in the N-
terminal part of C3 region showed high diversity (Fig. 2), and some
of these amino acid residues were potentially under positive
selection (Fig. 5).
Involvement of APOBEC3 activity in amino acid
substitutions due to the positive selection of Env
The sub-lethal level of APOBEC3 activity is proposed to be
involved in viral evolution; therefore, we attempted to study the
possible involvement of APOBEC family protein-mediated G to A
mutation in the positive selection of Env amino acid residues.
APOBEC3G and APOBEC3F are involved in GG-AG [41] and
GA-AA mutations [42], respectively. We manually detected GG-
AG, GA-AA, GC-AC and GT-AT mutations, and found one of
these mutation patterns 44 times over 3 years at 21 out of 47
amino acid residues with a dN/dS ratio greater than 1 (45%) in
the C1, C2, V3, C3, C4 and C5 regions of gp120 and gp41
(Table 3). G to A mutations were more frequently detected in
samples derived from individuals on ART, including CR17 and
CR19, compared to samples derived from drug-naive individuals
including CR2 and CR14 (Table 3), suggesting the accumulation
Table 2. Amino acid residues potentially under positive selection.*
Env regions Amino acid residue (dN/dS ratio, patient ID)**
gp120
C1 28 (1.03, CR28), 31 (2.43, CR19), 60 (1.05, CR36), 84 (6.24, CR17),
85 (1.14, CR14), 119 (1.46, CR17)
C2 212 (1.28, CR2), 240 (2.33, CR38), 261 (1.01, CR19), 263 (2.31, CR8),
290 (1.28, CR19)
V3 310 (1.54, CR8), 315 (1.07, CR28), 320 (2.57, CR36)
C3 332 (2.32, CR19), 335 (1.47, CR11), 336 (1.42, CR11), 341 (1.44, CR8),
346 (3.00, CR2; 3.20, CR8; 2.96, CR14; 2.30, CR38), 347 (1.23, CR38),
3499 (1.28, CR17),*** 350 (1.21, CR14), 351 (2.16, CR14), 354 (2.37, CR19),
359 (1.75, CR2; 1.92, CR38), 362 (1.54, CR19), 363 (1.79, CR8; 2.08, CR38),
364 (1.50, CR8), 365 (2.75, CR8), 367 (1.89, CR14), 370 (1.32, CR8)
C4 421 (1.53, CR14), 439 (1.42, CR38), 440 (16.34, CR12), 442 (1.99, CR14; 1.50,
CR29; 1.50, CR38), 447 (1.21, CR14), 450 (1.10, CR14), 454 (1.07, CR19)
C5 ND****
gp41 535 (1.61, CR38), 585 (1.78, CR36), 600 (1.03, CR8), 647 (1.01, CR17),
658 (1.76, CR2), 718 (1.60, CR17), 776 (1.93, CR2), 804 (3.14, CR19),
853 (1.35, CR17; 1.31, CR28)
*dN/dS ratio was determined as described in Methods, and the amino acid residue at which dN/dS ratio was greater than 1 was considered to be potentially under
positive selection.
**Amino acid numbering is according to that of HXB2 Env. dN/dS ratio and Patient ID are shown in parentheses.
***Inserted amino acid residue between position 349 and 350.
****Not detected.
doi:10.1371/journal.pone.0027098.t002
Figure 5. Amino acid residues potentially under positive selection in the C3 region of Env gp120. The dN/dS ratio was estimated for
each amino acid residue in the C3 region of gp120 among 10 amino acid sequences derived from an individual, as described in Methods. The data
obtained from 15 patient samples were then plotted together. Amino acid numbering is based on the HXB2 Env gp120.
doi:10.1371/journal.pone.0027098.g005
Evolution of CRF01_AE Viruses
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limited viral replication. Nevertheless, these results suggested that
APOBEC3 activity was involved, at least in part, in mutations due
to the positive selection of Env gp120 and gp41.
Discussion
The molecular evolution of CRF01_AE Env was studied using
viral gene fragments periodically collected from 15 chronically
HIV-1-infected Thai patients over 3 years. It was previously
reported for subtype B Env that the V1/V2 regions of gp120 are
under positive selection in vivo [43], and the expansion of V1/V2
regions along with the accumulation of PNLG sites reduces the
susceptibility of viruses to autologous neutralizing antibody [28].
The V3 region of subtype B gp120 shows strong immunogenicity,
and several neutralizing monoclonal antibodies have been
established [23,24,27]. In addition, the positive selection of amino
acid residues in the V3 region is reported [44,45,46]. In contrast,
the V3 region of subtype C gp120 is conserved, and the molecular
evolution of C3-V4 regions is observed under the selection
pressure of autologous serum antibodies [29]. In addition, the V5
region, cooperating in part with the V3 region, of subtype C gp120
is involved in generating an escape variant against humoral
immune responses [47]. We first attempted to identify the region
of CRF01_AE Env that showed high variability over 3 years, and
found that the V1/V2, V4 and V5 regions of CRF01_AE gp120
showed high variability (Fig. 1). The gp120 region that showed
highest variability was different among patients, suggesting that
the V1/V2, V4 or V5 regions differentially counteracts with
humoral immune responses. In contrast to these regions, the V3
region showed relatively low variability among the variable regions
of gp120 (Fig. 1). The vast majority of CRF01_AE Env clones
derived from plasma samples were CCR5-tropic [48]. In addition,
CCR5-tropic CRF01_AE viruses with a low positive charge in the
V3 region show low neutralization susceptibility to anti-V3
antibodies [49]. Considering these reports together, the V3 region
of CCR5-tropic CRF01_AE viruses may not be under strong
selection pressure of humoral immune responses in chronically
infected, asymptomatic patients.
Molecular evolution of the C3 region of subtype C gp120 was
previously reported [50]. An alpha helix domain located in the N-
terminal part of the C3 region of subtype C gp120 shows high
variation and is under positive selection, whereas that of subtype B
gp120 is relatively conserved [1,51]. In addition, the quaternary
structure of this region differs between subtype B and C Env [52],
and the C3 region of subtype C, but not of subtype B gp120 is
suggested to be under immune pressure. Furthermore, mutations
in the C3 region, cooperating with those in the variable regions, of
subtype C gp120 affect the neutralization susceptibility of viruses
to autologous neutralizing antibodies [53]. Our results showed that
the C3 region of CRF01_AE gp120, similar to that of subtype C
gp120, showed high amino acid variation (Figs. 1 and S1), and was
suggested to be under the selection pressure of autologous immune
responses.
Viral evolution in patients on ART has been reported
previously [45]. Consistent with the previous report, high
variability was observed in the variable regions of gp120 derived
not only from drug-naı ¨ve patients, but also from patients on ART
(Fig. 1). We observed not only a gradually increasing pattern, but
also a fluctuating pattern in the chronological change in the
variability of Env amino acid sequences over 3 years (Fig. 1),
indicating two possibilities: that the variability was generated by
the evolution of a trace of escape mutants against ART or was due
to viral quasispecies which acquired divergence prior to the onset
of ART. The frequent appearance of stop codons in the C2, V3
and C3 regions of gp120 in proviral DNA derived from
successfully treated patients is reported [54]. In contrast to the
previous report, premature stop codons were not frequently
detected in Env gp120 and gp41 derived from patients on ART
(data not shown). A possible explanation for this discrepancy might
be the difference in efficacy, including the potency and the level of
adherence, of ART between patients enrolled in our and other
studies.
Potential APOBEC3 family protein-mediated G to A mutations
were detected among the mutations due to the positive selection of
several Env amino acid residues (Table 3), suggesting the role of a
sub-lethal level of APOBEC3 activity in viral evolution. APO-
BEC3G introduces missense or nonsense mutations into viral
DNA during the RT process and leads to a diminishment of viral
infectivity, whereas HIV-1 Vif counteracts this activity [5,7,8];
therefore, we consider that an approach to inhibit Vif function or
stimulate APOBEC3 activity has potential for therapy.
Table 3. Association of positive selection and potential
APOBEC3-related mutation.
Env regions
Amino acid
residue* Patient ID G to A mutation**
gp120
C1 28 CR25 GG to AG x3***
31 CR19 GA to AA
60 CR36 GG to AG
84 CR17 GA to AA
85 CR8 GG to AG
C2 290 CR19 GA to AA x2, GT to AT
CR29 GA to AA x2, GT to AT
C3 332 CR11 GA to AA x2
CR19 GT to AT
335 CR11 GA to AA x2, GG to AG
346 CR2 GA to AA
347 CR38 GA to AA x3
350 CR14 GG to AG, GA to AA
CR17 GG to AG x2
362 CR19 GA to AA
C4 439 CR19 GT to AT
440 CR12 GG to AG
CR17 GG to AG
442 CR29 GA to AA
CR38 GA to AA
454 CR19 GA to AA
gp41 535 CR38 GA to AA x2
585 CR36 GT to AT x2
600 CR8 GA to AA x3
647 CR17 GG to AG
658 CR2 GA to AA x2
*Amino acid residues are numbered according to HXB2 Env protein.
**Mutations, GG to AG, GA to AA, GC to AC and GT to AT, at amino acid residues
with dN/dS ratio .1 were manually detected.
***GG to AG mutation was sequentially detected 3 times among 10 Env amino
acid sequences derived from an individual.
doi:10.1371/journal.pone.0027098.t003
Evolution of CRF01_AE Viruses
PLoS ONE | www.plosone.org 9 November 2011 | Volume 6 | Issue 11 | e27098Finally, HIV-1 Env, gp120 and gp41 are the major targets
among viral proteins of humoral immune responses to viral
infection; therefore, they are candidates of vaccine antigens. In
order to develop an effective vaccine, it is important to understand
the immunological characteristics of target viral proteins; however,
information regarding the molecular evolution of CRF01_AE Env
is still limited. CRF01_AE is a major circulating recombinant form
of HIV-1 prevalent in Southeast Asia, including Thailand, and
HIV vaccine trials have been conducted in Thailand [55,56]. We
hope that our results may provide useful information for
understanding the immunological characteristics of CRF01_AE
Env as well as for designing effective vaccine antigens.
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